Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi


  • Alvaro Torres-Huerta
  • Estefania Aleman-Navarro
  • Maria Elena Bravo-Adame
  • Monserrat Alba Sandoval-Hernandez
  • Oscar Arturo Migueles-Lozano
  • Yvonne Rosenstein
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_523


Historical Background

CD43, also called sialophorin or leukosialin, was first identified as a defective molecule of leukocytes and platelets of patients affected with the Wiskott–Aldrich syndrome, yet the molecule responsible for this immunodeficiency turned out to be WASP. It was thought that expression of this heavily glycosylated, mucin-type membrane protein was restricted to hematopoietic cells. However, recent advances in the field evidence that CD43 is present in non-lymphoid tissues, particularly tumor cells. Here we reviewed the most important features about this molecule, highlighting the recent advances that have contributed to our understanding of the roles of CD43.

Gene Expression and Protein Structure

CD43 is a type I cell surface glycoprotein abundantly expressed on almost all hematopoietic cells, except for erythrocytes and resting B cells. Although initially considered an immune cell molecule, recent reports evidence a much broader distribution, as epithelial cells, and a range of tumors of epithelial origin are CD43 positive. Expression of CD43 has also been documented in the normal brain and in the uterus. The gene encoding human CD43 is located in chromosome 16; it has two transcription initiation sites, and it is composed of two exons and a single intron within the untranslated 5′ region, although the entire protein is encoded only by the second exon. Alternative polyadenylation signals generate two mRNAs that differ from each other in the length of the 3′ untranslated region (Pallant et al. 1989).

CD43 is a bulky and extended cell surface mucin that protrudes 45 nm from the cell surface. Its 239-amino acid-long extracellular domain comprises five tandem repeats of 18 amino acids each (116Ile–205Ser), rich in serines and threonines modified by O-GalNAc glycosylation. As a result of the timely controlled activity of core 2 β-1,6-N-acetylglucosaminyltransferase (C2GnT), two isoforms of CD43 that define cell interaction affinities and functional cell states have been characterized. A 115 kDa isoform is expressed preferentially in thymocytes, resting CD4 T lymphocytes and monocytes, and a 130 kDa isoform is detected in resting CD8, CD4-activated T lymphocytes, neutrophils, platelets, B lymphocytes and macrophages, as well as tumor cells. The low molecular isoform contains almost exclusively the tetrasaccharide NeuAc(α2-3)-Gal(β1-3)[(NeuAc(α2-6)]GalNAc (Core1), and the high molecular isoform contains mainly the branched hexasaccharide NeuAc(α2-3)-Gal(β1-3)[NeuAc(α2-3)Gal(β1-4)GlcNAc(β1-6)]Gal-NAc (Core2) (Fukuda 2002). The intracellular domain contains 123 amino acids with a highly conserved sequence among primates, mouse, and rat; it includes different motifs (Fig. 1) that allow CD43 to participate in different signaling pathways, supporting a functional role for this molecule.
CD43, Fig. 1

Multiple alignment of the intracellular region of CD43. Sequences are the reported on NCBI or were obtained by a BLAST analysis and picking the hits with at least 80% identity. The Pan troglodytes, Pongo abelii, Rattus novergicus, Canis familiaris, Callithrix jacchus, and Equus caballus sequences are computational predictions. Two binding sites for ERM family proteins (ezrin, radixin, moesin) are highly conserved between species (blue letters, amino acids 1–20 and 61–77). Two nuclear localization signals (NLS, yellow-shaded residues), comprising residues 5–19 and 61–75 of the intracellular domain, respectively, overlap with the ERM-binding domains. Potential phosphorylation sites are also located within the NLS- and ERM-binding regions. Serine/threonine residues experimentally confirmed to be phosphorylated in human, and well conserved, are marked with a “#” symbol. Red-colored letters represent predicted cAMP- and cGMP-dependent protein kinase phosphorylation sites (residues 5–8 and 71–74). Pink letters and purple-shaded letters tag predicted protein kinase C phosphorylation pattern sites (residues 59–61 and 91–93). Between the two ERM-binding domains, potential casein kinase II phosphorylation sites are predicted (brown-shaded letters, residues 44–47, and 45–48 in Equus caballus). In addition, three potential SUMO modification consensus sequence sites (ψKXE) located close to the C-terminus (orange letters) have been identified in the murine CD43 protein (residues 84–87, 92–95, 117–120; the middle one is well conserved across species). Finally, a proline-rich region (green-shaded letters) at the C-terminus allows SH3 domain-containing proteins to bind and participate in CD43 signaling pathways (Reviewed in Aguilar-Delfin et al. 2006; Seo and Ziltener 2009)

CD43 Expression Is Tightly Controlled

The levels and relative abundance of CD43 on the cell surface are regulated through several mechanisms: expression regulation, molecular density, or processing, evidencing a regulatory role for CD43 in cell function.

Aside from a tissue-specific gene transcription regulation, the relative abundance of CD43 at a specific location of the cell membrane is tightly controlled. As T lymphocytes and neutrophils migrate to inflammatory lesions, CD43, together with PSGL-1, ICAM-3, and CD44, moves from the leading edge to the rear end (uropod) of the cell through its association with and movement of ERMs, while chemokine receptors relocate at the leading edge. Likewise, and through a similar mechanism, during the encounter of an antigen-specific T cell with the appropriate antigen-presenting cell, CD43 is excluded from the immunological synapse and relocates partially to the distal pole, where it plays a yet to define role. Interestingly, it is excluded from the inhibitor natural killer (NK) cell synapse, but not from the activating one (Reviewed in Ostberg et al. 1998; Aguilar-Delfín et al. 2006).

In addition, CD43 expression is regulated by proteolysis and shedding. Processing of CD43 has been described in human neutrophils and in murine T lymphocytes, as well as in human carcinoma cell lines (Lopez et al. 1998; Andersson et al. 2004; Seo and Ziltener 2009). The enzymatic cleavage of CD43 by a γ secretase-dependent intramembrane processing mechanism leads to the shedding of the extracellular domain, known as galactoglycoprotein and present in high concentrations in normal serum, and to the translocation of the intracytoplasmic domain to the nucleus, where it has been found to protect cells from apoptotic signals, promoting cell survival (Andersson et al. 2004; Seo and Ziltener 2009). Lastly, secretion of intracellularly stored CD43 is yet another mechanism through which CD43 expression levels are regulated: following LPS exposure, the intracellular levels of CD43 present in intestinal epithelial cells have been found to augment and correlate with an important secretion of CD43 to the intestinal lumen, underscoring a role for this mucin as a defense mechanism against infection in the intestinal epithelium (Amano et al. 2001).

A Multifunctional Protein

The abundance of CD43, its elongated structure, and the high sequence homology of its intracytoplasmic domain between species indicate that this molecule transduces information from the cell surface to the intracellular milieu in order to modulate the decisions of the cell. In line with the fact that CD43 has been found to partner with a seemingly ever-growing list of membrane molecules, multiple but often opposing functions have been described for CD43. The capacity of CD43 to transduce activation signals that regulate these multiple functions relies on its intracytoplasmic domain. Depending on the cell, and most probably on the ligand it encounters, CD43 must activate different signaling pathways that ultimately fine-tune the decision-making process of the cell, although little is known about this.

The net negative charge of CD43, resulting from the elevated glycosylation and sialic acid content, led to first propose that the role of this abundantly expressed cell surface mucin was to provide the cells with a repulsive force to limit cell contacts. Further attempts to understand the role of CD43 have been undertaken in vivo with the CD43−/− mice, with different disease models where T lymphocytes are pivotal. In a model of vaccinia virus infection, despite the fact that CD8-dependent cytotoxic response is more robust in the knockout mice, viral clearance is less efficient in these mice as compared to wild-type animals (Manjunath et al. 1995). Infiltration of naïve CD8+ T cells to the brain following intracranial infection with lymphocytic choriomeningitis virus (LCMV) is impaired in CD43−/− mice, resulting in prolonged survival of the animals. Likewise, In an experimental model of autoimmune encephalomyelitis (EAE), CD43−/− mice have a lower incidence rate of the disease and milder symptoms due to a defective migratory capacity of antigen-specific CD4 T cells to the central nervous system. In addition, and consistent with the reduced inflammation, these animals have higher levels of IL-4 rather than of IFNγ. The LCMV model also provides evidence that in addition to regulate the migration of T lymphocytes, CD43 participates in the contraction phase of the response, as antigen-specific CD8+ T-cell numbers remain higher in the knockout mice due to enhanced levels of  Bcl-2 and hence decreased apoptosis (Onami et al. 2002; Ford et al. 2003). Another example of the involvement of CD43 in migration is provided by a murine model of elastase-induced abdominal aortic aneurysm (AAA), showing that CD43−/− mice are resistant to the development of such pathological condition due to a reduced recruitment of T cells and macrophages to the aortic wall. Moreover, CD43-mediated susceptibility to AAA depends on augmented IFNγ production by CD43+ CD8+ T cells, thus inducing higher levels of apoptosis in vivo and promoting extracellular matrix degradation (Zhou et al. 2013).

Altogether, this data highlight a positive role of CD43 in regulating the migration of naïve T cells to inflammation sites and in regulating cell number and homeostasis. This in turn determines the development and the outcome of the disease and correlates with the fact that anti-CD43 antibodies prevent the migration of T cells to pancreatic islands and, hence, the development of diabetes (Johnson et al. 1999). However, most of these studies were done in the mixed background BL6.129, and care should be taken in the interpretation of the data, as a mixed genetic background can influence the outcome of the experiments. Also, it should be taken into account that these animals are completely deficient for CD43. It will be interesting to evaluate the function of this mucin in mice where CD43 deficiency is targeted to a specific cell type.

In addition to interact with cytoskeletal elements and to participate in directing cell migration (Allenspach et al. 2001), CD43 regulates cell–cell interactions and activation (Fig. 2). Recent data indicate that CD43 signaling prepares human T cells to receive cytokine and differentiation signals by increasing the expression of IFNγR and IL-4R, promoting IFNγR–TCR co-clustering as well as the phosphorylation of their respective target transcription factors, STAT1 and STAT6 (Galindo-Albarrán et al. 2014). In addition, in neonatal cells, differentiation and maturation toward a Th2 phenotype is influenced by the CD43-induced IL-4R expression and IFNγ/IL-4 production, underscoring a differential role for CD43 depending on the T-cell maturational stage. In vitro, CD43 engagement has been shown to induce homotypic cell adhesion, dendritic cell maturation, monocyte respiratory burst, increased T- and B-cell proliferation, and cytokine and chemokine secretion in NK cells, mast cells, dendritic cells, and T cells. Depending on the cell model, CD43 has been reported to induce apoptosis (Jurkat cells and bone marrow) or, on the contrary, to promote cell survival (T and B lymphocytes). CD43 is only expressed on a small proportion of naive B cells; however, its expression is upregulated upon stimulation and it contributes to cell proliferation. Furthermore, forced expression of CD43 into a CD43- B-cell lymphoma was shown to inhibit B-cell G1 arrest, extending B-cell survival and retarding apoptosis (Misawa et al. 1996). Consistent with the fact that expression of CD43 on B-cell lymphomas correlates with a bad prognosis, uncontrolled proliferation and enhanced survival capacity, two hallmarks of tumor cells, are positively regulated by CD43 in B-cell lymphomas (Reviewed in Aguilar-Delfín et al. 2006 and Pedraza-Alva and Rosenstein 2007). Recently, human CD43+ B cells from peripheral blood of healthy individuals have been characterized at the phenotypic and developmental level. These CD43+ B cells phenotypically resemble memory B cells in their profile of surface receptors and the lack of IgG and IL-10 secretion. However, CD43+ B cells have a closer developmental relationship to plasmablasts than memory B cells, as plasmablasts can be induced from CD43+ B cells in vitro, although no in vivo assays were performed (Inui et al. 2015).
CD43, Fig. 2

The signaling pathway of CD43 has been best characterized in T cells, where it functions as a co-receptor of the TCR and its co-stimulatory function is independent of CD28 (Sperling et al. 1995). CD43+TCR co-stimulation results in the Lck-dependent tyrosine phosphorylation of pyruvate kinase isozyme M2 (PKM2) and activation of signal transducer and activator of transcription 3 (STAT3). In addition, TCR+CD43 engagement leads to the regulation of ERK5 downstream targets such as increased Bad phosphorylation, upregulation of c-Myc and cyclin D1 expression, activation of the NFκB pathway, and upregulation of the PKA/adenylyl cyclase (AC)-dependent CREB activation, underscoring a role for CD43 in promoting cell survival through non-glycolytic functions of metabolic enzymes (Bravo-Adame et al. 2016). Additional to its role as a co-stimulatory molecule, CD43 also signals by itself. CD43 engagement in human T cells induces its association to the  Src family kinases Lck and Fyn, through the interaction of their SH3 domains and the proline-rich region of CD43. This then leads to the phosphorylation of the CD3 ζ chain and the assembly of macromolecular complexes that include adaptor proteins such as Shc, Grb2,  SLP-76, and the guanine exchange factor  Vav. These signaling complexes promote ERK1/2 MAPK activation, leading to regulation of actin cytoskeleton and a positive feedback loop for Lck signaling as a result of an ERK1/2-dependent serine phosphorylation of Lck, which inhibits its association to the phosphatase SHP-1. CD43 engagement also induces calcium fluxes and PKC activation, necessary for Cbl serine phosphorylation and its interaction with 14-3-3. Moreover, T-cell pre-stimulation by the CD43 co-receptor molecule before TCR engagement inhibits the TCR-dependent c-Cbl tyrosine phosphorylation and interaction with the adapter molecule Crk-L, and promotes Cbl-b ubiquitination and degradation in a PKC θ-dependent manner. The inhibition of these E3 ubiquitin ligases results in prolonged tyrosine phosphorylation and delayed degradation of  ZAP-70 and of the CD3 ζ chain, leading to enhanced MAPK activation and robust T-cell response. These data indicate that CD43-mediated signals lower the threshold for T-cell activation by restricting the c-Cbl and Cbl-b inhibitory effects on TCR signaling (Reviewed in Pedraza-Alva and Rosenstein 2007)

Multiple Ligands for a Multifunctional Protein

The diversity of the physiological ligands identified for CD43 evidences a dynamic role for this cell surface mucin in regulating intercellular interactions and cell function. The fact that ICAM-1 and MHC-1 molecules have been found to act as receptors for CD43 (Reviewed in Pedraza-Alva and Rosenstein 2007), together with the recent finding that CD43 interacts with LFA-1 and CD147 in two distinct complexes (Khunkaewla et al. 2008), indicates that CD43 plays a role in cell–cell adhesion, in concert with, and probably regulating, other adhesion molecules. Consistent with this possibility, splenocytes and thymocytes from CD43-deficient mice exhibit enhanced homotypic adhesion to ICAM-1 and fibronectin (Manjunath et al. 1995). Paradoxically, in contrast with this anti-adhesive function, a number of anti-CD43 mAbs block homotypic cell–cell interactions or lymphoid cell binding to lymph nodes and high endothelial venules (Reviewed in Ostberg et al. 1998 and in Aguilar-Delfín et al. 2006). Furthermore, E-selectin has been found to interact with CD43, favoring Th17 cells and neutrophil and B-cell leukemia cell lines rolling on activated vascular endothelium, further evidencing the participation of CD43 as a pro-adhesive molecule that regulates the infiltrating ability of cells (Matsumoto et al. 2008; Nonomura et al. 2008; Velázquez et al. 2016). CD43 also interacts with Siglec-1 (sialoadhesin), a regulator of lymphoid and myeloid cell adhesion, probably consolidating physical contacts between cells. On the contrary, the putative association of CD43 to human serum albumin inhibits neutrophil function by limiting cell spreading as well as CD43 proteolysis by elastase (Reviewed in Aguilar-Delfín et al. 2006). Altogether, these data support the idea that CD43 triggers signaling pathways that modulate other conventional adhesion mechanisms.

In human dendritic cells, galectin-1–CD43 interaction primes the cells and results in cytokine production, upregulation of metalloproteases, and increased migration, through signaling pathways that depend on calcium fluxes as well as on Syk and Protein kinase C activation. However, through its interaction with galectin-1, CD43 promotes T-cell apoptosis, possibly by recruiting galectin-1 molecules to the cell surface and making them accessible to CD7, which is directly responsible for galectin-1-induced cell death (Hernandez et al. 2006; Fulcher et al. 2009). Interestingly, through the interaction of membrane nucleolin with capped CD43, macrophages recognize apoptotic cells (Miki et al. 2009).

The myriad of ligands underscores a regulatory role for CD43, ultimately favoring homeostasis of the immune system. Since most of these molecules are also ligands for other receptors, and different functions have been associated to each of them, this data underscores a role for CD43 in the fine-tuning of cell fate. However, information about the cellular responses and the intracellular signals that result from the interaction of CD43 with each of its ligands is very fragmentary, and this is undoubtedly a question that needs to be addressed.

CD43 Is a Pathogen Recognition Receptor

The complex glycosylation pattern of CD43 functions as bait for multiple pathogens. During HIV infection, as a result of increased Core2 enzyme activity, more O-Core2 glycans and lactosamine residues decorate CD43, ultimately leading infected cells to apoptosis, presumably as a result of the interaction of galectin-1 with CD43 and CD45. Moreover, it was suggested that this pathway can contribute to the death of infected as well as noninfected cells and thus to a decrease in T-cell counts (Lanteri et al. 2003). What is more, the combination of CD43 and TCR– CD3 complex signals lowers the signaling threshold for HIV LTR-driven gene activity, promoting the activation of NFκB and  NFAT, ultimately favoring viral replication (Barat and Tremblay 2002). In addition, the alternative glycosylation of CD43 promotes the production of autoantibodies against hyposialylated isoforms, although their role in HIV pathogenesis is not understood (Reviewed in Pedraza-Alva and Rosenstein 2007).

Influenza A virus (IAV) was also found to interact with polymorphonuclear leukocytes through the specific interaction of CD43 with the IAV hemagglutinin. In addition to lessen the oxidative burst of these cells, IAV modifies the expression level of adhesion-related molecules: while it reduces that of CD43 and L- and P-selectins, it augments that of integrins CD11b and CD11c, subtly modulating the adhesive interactions of polymorphonuclear cells (Hartshorn and White 1999). It is presently not known if this is the result of the signals transduced by the CD43–hemagglutinin A interaction or if it reflects the activation of additional, CD43-independent pathways.

Several pathogenic bacteria also use CD43 as a pathogen recognition receptor (PRR). Recent reports have defined Cpn60.2 (Hsp65, GroEL), a molecular chaperone and an adhesin of the capsule of Mycobacterium tuberculosis, as a ligand for CD43 (Hickey et al. 2010). This is consistent with the fact that on macrophages, CD43 was previously identified as a receptor for M. tuberculosis, taking part in bacillus uptake and limiting its intracellular growth through the production of TNFα (Fratazzi et al. 2000). Additionally, three single-nucleotide polymorphisms (SNPs) in the CD43 gene region found in a Vietnamese population were associated with susceptibility to tuberculous meningitis (TBM) in a recessive model of inheritance. Two of these SNPs are associated with disease severity, and one of them is also associated with decreased survival of patients with TBM, but the underlying mechanism is not known (Campo et al. 2015). Streptococcus gordonii, the causative agent of infective endocarditis, has also been found to specifically interact with CD43 through HSA, another adhesin (Ruhl et al. 2000). More recently, CD43 was reported to be the substrate of a mucinase secreted by enterohemorrhagic Escherichia coli, the enteric pathogen that causes hemorrhagic colitis. The net balance of the proteolytic activity of this metalloprotease is the cleavage of the extracellular domain of CD43 from neutrophils, increased oxidative burst, but impaired neutrophil motility (Szabady et al. 2009).

In addition, CD43 is a counter-receptor for the trans-sialidase of Trypanosoma cruzi, the causative agent of Chagas disease. This enzyme transfers sialic acid from β-galactopyranosil donors to β-galactopyranosil acceptors with α2–3-linkages providing the parasite with a disguise to avoid recognition by the host immune system. Furthermore, it restores the glycosylation status of CD43 to a Core1 glycan expression pattern, similar to that of resting T cells, thus compromising the T-cell-dependent response, ensuring parasite replication. Interestingly, T. cruzi produces large amounts of an inactive and soluble form of the trans-sialidase that is also recognized by CD43, although the biological significance of this is not understood (Freire-de-Lima et al. 2010).

On non-lymphoid cells, CD43 retains the capacity to function as PRR. Together with the glycolipid GM1, CD43 has been described as a receptor for the heat-labile enterotoxin (LT) of enterotoxigenic E. coli in the microvilli of enterocytes (Zemelman et al. 1989). Interestingly, in CaCo2 cells differentiated into enterocytes, CD43 is not exposed on the cell surface, but stored in intracellular granules from where it is released and secreted to the extracellular compartment upon exposure of the cells to bacterial lipopolysaccharides (Amano et al. 2001).

Altogether, these data suggest that through the pathogen receptor function of CD43, PAMPS initiate a signal transduction pathway that promotes the activation of target cells and the onset of an inflammatory response and inflammation-related diseases. A better understanding of the specific role of CD43 in the pathogen recognition and the cell surface association processes will provide a clue to identify key target molecules both on the bacteria and on the host’s cells.

CD43 and Noninfectious Diseases: A Poorly Understood Function

In addition to function as a PRR, CD43 has been associated to diverse diseases. CD43 was first described as the molecule responsible for the Wiskott–Aldrich syndrome (WAS), an immunodeficiency characterized by frequent infections, skin eczema, decreased platelet numbers, and defective T-cell function (Remold-O’Donnell et al. 1984). However, it was later demonstrated that this X-linked disease was caused by mutations in the gene encoding WASP, a protein involved in signal transduction from cell receptors to the actin cytoskeleton. Yet, the link between WASP and CD43 is still unclear.

Although the participation of CD43 in several autoimmune diseases is documented, we are still lacking the full picture regarding the mechanisms of pathogenesis associated to this. Decreased expression of CD43 on the cell surface of synovial fluid polymorphonuclear cells of rheumatoid arthritis patients (Humbria et al. 1994), while an enhanced expression on the T cells infiltrating the synovium of osteoarthritis patients (Sakkas et al. 1998) have been reported. In systemic lupus erythematosus (SLE) patients, anti-CD43 and anti-galectin-1 autoantibodies, together with high levels of soluble galectin-1, were found to correlate with the time of disease evolution and low levels of complement (Montiel et al. 2010). Unusual high intracellular calcium levels, observed in pathological conditions such as systemic lupus erythematosus (SLE), Alzheimer’s disease, and brain trauma, result in capping of CD43. Similar to what happens with apoptotic cells, capped CD43 interacts with the macrophage receptor nucleolin, leading to recognition and phagocytosis of viable cells with elevated intracellular calcium levels by macrophages (Miki et al. 2013).

A role for CD43 in type I diabetes has been suggested, as preventing T-cell migration and possibly that of other CD43+ cells such as monocytes and dendritic cells from bloodstream to inflammation sites (lymph nodes, pancreas, and salivary glands) with exogenous anti-CD43 antibodies inhibits the progression of the disease (Johnson et al. 1999). Thus, reflecting the dual nature of CD43, anti-CD43 antibodies could favor the inflammatory response, exacerbating the disease (SLE and arthritis), or prevent the establishment of the disease (diabetes). Likewise, CD43 functions as a major ligand for E-selectin on activated vascular endothelium, regulating lymphocyte trafficking and favoring the recruitment of CD4+ Th17 cells to the insult site. Particularly, injection of CCL20 or TNFα into an air pouch of CD43−/− mice results in an impaired recruitment of Th17 or Th1 and Th17 cells, respectively. Furthermore, consistent with the fact that EAE is a disease where Th17 cell recruitment into the CNS plays a critical pathogenic role and that CD43−/− mice do not develop EAE, CD43 regulates the recruitment of Ag-specific Th17 cells in the murine model of EAE (Velázquez et al. 2016).

CD43 and Tumor Development: A Productive but Complex Association

CD43 has long been considered as a leukocyte-restricted molecule, and it has been mostly studied in leukocytes. Accordingly, this sialomucin is expressed in more than 90% of T-cell lymphomas and T-cell lymphoblastic lymphomas (Leong et al. 2003). In the B-cell lineage, contrasting with the limited expression of CD43 on normal early B cells and activated peripheral B cells, in transformed cells, CD43 is expressed at other B-cell stages, particularly in B-cell lymphoblastic (70%) and low-grade B-cell (30%) lymphomas (Leong et al. 2003). CD43 expression in B-cell lymphomas is associated to a bad prognosis.

In addition to hematopoietic tumors, non-hematopoietic tumor-derived cells from the breast, lung, colon, bladder, cervix, and prostate express CD43 (Reviewed in Aguilar-Delfin et al. 2006), mostly in the early stages of tumor development. Remarkably, in non-hematopoietic cancer cells, CD43 has mostly an intracellular localization in opposition to the typical membrane-bound one on leukocytes (Andersson et al. 2004; Fu et al. 2013). CD43 was first identified in the colon carcinoma cell lines COLO 205 as a 200 kDa molecule, supporting a role for aberrant glycoforms of CD43 in cancer development. Besides generating unusual epitopes that potentially serve as malignancy markers, CD43 influences the interaction of cancer cells with their microenvironment at different levels, resulting in enhanced cell proliferation, increased ability to invade and metastasize, as well as regulated interactions between the tumor cells and the intra-tumoral immune environment, eventually promoting resistance of the tumor cells to CTL-mediated lysis and the establishment of a microenvironment favorable to tumor growth (Andersson et al. 2004; Fu et al. 2013; Camacho-Concha et al. 2013; Tuccillo et al. 2014; Hasegawa et al. 2016).

Recently, CD43 was shown to participate in the tumor cell–peritoneum interaction, through a metalloprotease-dependent mechanism activated by the interaction with ICAM-1, one of its putative ligands (Alkhamesi et al. 2007). In addition, the proteolytic cleavage of the CD43 cytoplasmic domain (CD43-ct), through a regulated intramembrane proteolysis process (RIP), exposes a nuclear localization signal that promotes the translocation of the truncated protein to the nucleus, where it interacts with β-catenin, resulting in increased expression of the c-Myc and cyclin D1 genes (Andersson et al. 2004, 2005). In the absence of the tumor suppressors p53 and/or ARF, overexpression of CD43 in a human colon carcinoma cell line interferes with FAS expression and thus protects the cells from FAS-mediated apoptosis, ultimately favoring cell proliferation. Interestingly, the full-length molecule can be also found in the nucleus bound to the chromatin, reducing the level of FAS and activating the ARF/p53 pathway (Kadaja et al. 2004; Kadaja-Saarepuu et al. 2008), revealing a complex interplay between the full-length molecule and the CD43-ct peptide. In addition to being modified by SUMO-1 peptides, the cytoplasmic domain of CD43 has been found to localize with PML (promyelocytic) nuclear bodies (Seo and Ziltener 2009), further supporting a role for CD43 in promoting cell survival and carcinogenesis. This data suggests that different peptides perform different functions, ultimately fine-tuning cell function when acting in concert.

Consistent with the fact that CD43 was found to be mostly expressed in early-stage colon carcinomas and that in early stage some tumors accumulate p53, CD43 was reported to prolong the half-life of p53 by inducing its phosphorylation on Ser15, possibly in an ERK1/2-mediated process. This in turn disrupts the binding of p53 with the Mdm2 ubiquitin ligase and triggers p53-dependent cellular responses such as promoting the expression of Mdm2 and p21 cyclin-dependent kinase (Kadaja et al. 2004).

Altogether, these data demonstrate that CD43 participates in the coordinated regulation of cell adhesion and cell motility as well as in the control of cell cycle entry, ultimately favoring cell transformation, tumor formation, and invasiveness (Fig. 3). A deeper understanding of the CD43-mediated signals involved in tumor cell proliferation or survival will be critical for the rational development of drugs aimed to reduce malignancy.
CD43, Fig. 3

The interaction of CD43 with its ligands may induce the proteolytic processing of the molecule through a γ secretase-dependent mechanism. The resulting peptides, the extracellular domain (Galgp), and the intracellular domain (CD43-ct) each play specific roles to tailor the tumor cell behavior. When overexpressed by a human colon adenocarcinoma (Laos et al. 2006), CD43 was found to contribute to oncogenesis by downregulating the expression of immune response genes such as the chemokines MCP-1, IL-8, and GRO-α, through a mechanism depending on reduced transcriptional activity of NFkB p65 but not p50 (Laos et al. 2006). In addition, full-length CD43 and CD43-ct migrate to the nucleus through a RAN-transporter-mediated mechanism and together with β-catenin regulate the expression of genes that favor cell cycle entry, proliferation, and survival (Balikova et al. 2012). In addition, CD43 abrogates contact inhibition of growth through the AKT-dependent phosphorylation and degradation of the tumor suppressor Merlin, thus enabling YAP to function as a transcriptional regulator in the nucleus, favoring the expression of genes involved in cell proliferation and survival (Camacho-Concha et al. 2013)


CD43 is a mucin that modulates the response of all cells of the immune system as well as that of other cells. Because of its elongated structure and its abundance on the cell surface, it serves as an antenna that senses the environment and prepares the cells for future actions. CD43 signals help the cell progress toward differentiation and maturation, as it regulates cell migration and cell contact. In addition, through the interaction with its numerous physiological and pathological ligands, CD43 actively participates in the onset of an inflammatory response and of inflammation-related diseases, underscoring the possibility to consider this molecule as a potential therapeutic target. An effort should be undertaken to identify those regions of the extracellular domain that are important for ligand recognition as well as to understand the rules that dictate selectivity of the different isoforms of CD43 for a given ligand. Unraveling the signals that follow interaction with a given ligand will help to untangle the multiple intracellular signals generated through this molecule. Understanding the role of soluble CD43 is also a challenge. A better appreciation of the functions regulated by the interaction of CD43 with each of its multiple ligands in different cells in diverse contexts of activation will provide a sharper picture of the roles this molecule plays in cell physiology in different organs, under normal and pathological scenarios.

See Also


  1. Aguilar-Delfin I, Fierro NA, Rosenstein Y. CD43. UCSD-nature molecule pages. 2006. doi:10.1038/mp.a000001.01.Google Scholar
  2. Alkhamesi NA, Roberts G, Ziprin P, Peck DH. Induction of proteases in peritoneal carcinomatosis, the role of ICAM-1/CD43 interaction. Biomark Insights. 2007;2:377–84.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Allenspach EJ, Cullinan P, Tong J, Tang Q, Tesciuba AG, Cannon JL, et al. ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Immunity. 2001;15(5):739–50.CrossRefPubMedGoogle Scholar
  4. Amano J, Morimoto C, Irimura T. Intestinal epithelial cells express and secrete the CD43 glycoform that contains core 2 O-glycans. Microbes Infect. 2001;3(9):723–8.CrossRefPubMedGoogle Scholar
  5. Andersson CX, Fernandez-Rodriguez J, Laos S, Sikut R, Sikut A, Baeckstrom D, Hansson GC. CD43 has a functional NLS, interacts with beta-catenin, and affects gene expression. Biochem Biophys Res Commun. 2004;316(1):12–7.CrossRefPubMedGoogle Scholar
  6. Andersson CX, Fernandez-Rodriguez J, Laos S, Baeckstrom D, Haass C, Hansson GC. Shedding and γ-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem J. 2005;387(Pt 2):377–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Balikova A, Jääger K, Viil J, Maimets T, Kadaja-Saarepuu L. Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol. 2012;41(1):299–309.PubMedGoogle Scholar
  8. Barat C, Tremblay MJ. Engagement of CD43 enhances human immunodeficiency virus type 1 transcriptional activity and virus production that is induced upon TCR/CD3 stimulation. J Biol Chem. 2002;277(32):28714–28724. Epub 2002 Jun 3.Google Scholar
  9. Bravo-Adame ME, Vera-Estrella R, Barkla BJ, Martínez-Campos C, Flores-Alcantar A, Ocelotl-Oviedo JP, et al. An alternative mode of CD43 signal transduction activates pro-survival pathways of T lymphocytes. Immunology. 2016. doi:10.1111/imm.12670.PubMedPubMedCentralGoogle Scholar
  10. Camacho-Concha N, Olivos-Ortiz A, Nuñez-Rivera A, Pedroza-Saavedra A, Gutierrez-Xicotencatl L, Rosenstein Y, et al. CD43 promotes cells transformation by preventing Merlin-mediated contact inhibition of growth. PLoS One. 2013;8(11):e80806. doi:10.1371/journal.pone.0080806. eCollection 2013.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Campo M, Randhawa AK, Dunstan S, Farrar J, Caws M, Bang ND, et al. Common polymorphisms in the CD43 gene region are associated with tuberculosis disease and mortality. Am J Respir Cell Mol Biol. 2015;52(3):342–8. doi:10.1165/rcmb.2014-0114OC.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Ford ML, Onami TM, Sperling AI, Ahmed R, Evavold BD. CD43 modulates severity and onset of experimental autoimmune encephalomyelitis. J Immunol. 2003;171(12):6527–33.CrossRefPubMedGoogle Scholar
  13. Fratazzi C, Manjunath N, Arbeit RD, Carini C, Gerken TA, Ardman B, et al. A macrophage invasion mechanism for mycobacteria implicating the extracellular domain of CD43. J Exp Med. 2000;192(2):183–92.Google Scholar
  14. Freire-de-Lima L, Alisson-Silva F, Carvalho ST, Takiya CM, Rodrigues MM, DosReis GA, et al. Trypanosoma cruzi subverts host cell sialylation and may compromise antigen-specific CD8+ T cell responses. J Biol Chem. 2010;285(18):13388–96.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Fu Q, Cash SE, Andersen JJ, Kennedy CR, Oldenburg DG, Zander VB, et al. CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target. Int J Cancer. 2013;132(8):1761–70. doi:10.1002/ijc.27873. Epub 2012 Oct 29.CrossRefPubMedGoogle Scholar
  16. Fukuda M. Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys Acta. 2002;1573(3):394–405.CrossRefPubMedGoogle Scholar
  17. Fulcher JA, Chang MH, Wang S, Almazan T, Hashimi ST, Eriksson AU, et al. Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem. 2009;284(39):26860–70.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Galindo-Albarrán AO, Ramírez-Pliego O, Labastida-Conde RG, Melchy-Pérez EI, Liquitaya-Montiel A, Esquivel-Guadarrama FR, et al. CD43 signals prepare human T cells to receive cytokine differentiation signals. J Cell Physiol. 2014;229(2):172–80.CrossRefPubMedGoogle Scholar
  19. Hartshorn KL, White MR. Influenza A virus up-regulates neutrophil adhesion molecules and adhesion to biological surfaces. J Leukoc Biol. 1999;65(5):614–22.PubMedCrossRefGoogle Scholar
  20. Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakano K, Kinoshita H, et al. Glycosylation status of CD43 protein is associated with resistance of leukemia cells to CTL-mediated cytolysis. PLoS One. 2016;11(3):e0152326. doi:10.1371/journal.pone.0152326. eCollection 2016.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Hernandez JD, Nguyen JT, He J, Wang W, Ardman B, Green JM, Fukuda M, Baum LG. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol. 2006;177(8):5328–36.CrossRefPubMedGoogle Scholar
  22. Hickey TB, Ziltener HJ, Speert DP, Stokes RW. Mycobacterium tuberculosis employs Cpn60.2 as an adhesin that binds CD43 on the macrophage surface. Cell Microbiol. 2010;12(11):1634–47.CrossRefPubMedGoogle Scholar
  23. Humbria A, Diaz-Gonzalez F, Campanero MR, Arroyo AG, Laffon A, Gonzalez-Amaro R, et al. Expression of L-selectin, CD43, and CD44 in synovial fluid neutrophils from patients with inflammatory joint diseases. Evid soluble form L selectin synovial fluid Arthritis Rheum. 1994;37(3):342–8.Google Scholar
  24. Inui M, Hirota S, Hirano K, Fujii H, Sugahara-Tobinai A, Ishii T, et al. Human CD43+ B cells are closely related not only to memory B cells phenotypically but also to plasmablasts developmentally in healthy individuals. Int Immunol. 2015;27(7):345–355. doi:10.1093/intimm/dxv009. Epub 2015 Mar 5.Google Scholar
  25. Johnson GG, Mikulowska A, Butcher EC, McEvoy LM, Michie SA. Anti-CD43 monoclonal antibody L11 blocks migration of T cells to inflamed pancreatic islets and prevents development of diabetes in nonobese diabetic mice. J Immunol. 1999;163(10):5678–85.PubMedGoogle Scholar
  26. Kadaja L, Laos S, Maimets T. Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF. Oncogene. 2004;23(14):2523–30.CrossRefPubMedGoogle Scholar
  27. Kadaja-Saarepuu L, Laos S, Jaager K, Viil J, Balikova A, Looke M, et al. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene. 2008;27(12):1705–15 .Epub 2007 Sep 24CrossRefPubMedGoogle Scholar
  28. Khunkaewla P, Schiller HB, Paster W, Leksa V, Cermak L, Andera L, Horejsí V, Stockinger H. LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147. Mol Immunol. 2008;45(6):1703–11.CrossRefPubMedGoogle Scholar
  29. Lanteri M, Giordanengo V, Hiraoka N, Fuzibet JG, Auberger P, Fukuda M, et al. Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death. Glycobiology. 2003;13(12):909–18.CrossRefPubMedGoogle Scholar
  30. Laos S, Baeckström D, Hansson GC. Inhibition of NF-kB activation and chemokine expression by the leukocyte glycoprotein CD43 in colon cancer cells. Int J Oncol. 2006;28(3):695–704.PubMedGoogle Scholar
  31. Leong AS, Cooper K, Leong FJ. Manual for diagnostic antibodies for immunohistology. 2nd ed. London: Greenwich Medical Media Ltd; 2003.Google Scholar
  32. Lopez S, Seveau S, Lesavre P, Robinson MK, Halbwachs-Mecarelli L. CD43 (sialophorin, leukosialin) shedding is an initial event during neutrophil migration, which could be closely related to the spreading of adherent cells. Cell Adhes Commun. 1998;5(2):151–60.CrossRefPubMedGoogle Scholar
  33. Manjunath N, Correa M, Ardman M, Ardman B. Negative regulation of T-cell adhesion and activation by CD43. Nature. 1995;377(6549):535–8.CrossRefPubMedGoogle Scholar
  34. Matsumoto M, Shigeta A, Miyasaka M, Hirata T. CD43 plays both antiadhesive and proadhesive roles in neutrophil rolling in a context-dependent manner. J Immunol. 2008;181(5):3628–35.CrossRefPubMedGoogle Scholar
  35. Miki Y, Itoh T, Hirano K, Eda S, Hayashi A, Yamanaka M, Beppu M. Clearance of oxidatively damaged cells by macrophages: recognition of glycoprotein clusters by macrophage-surface nucleolin as early apoptotic cells. Biol Pharm Bull. 2009;32(4):564–72.CrossRefPubMedGoogle Scholar
  36. Miki Y, Oguri E, Hirano K, Beppu M. Macrophage recognition of cells with elevated calcium is mediated by carbohydrate chains of CD43. Cell Struct Funct. 2013;38(1):43–54. Epub 2013 Feb 9.Google Scholar
  37. Misawa Y, Nagaoka H, Kimoto H, Ishii Y, Kitamura K, Tsunetsugu-Yokota Y, Shibuya M, Takemori T. CD43 expression in a B cell lymphoma, WEHI 231, reduces susceptibility to G1 arrest and extends survival in culture upon serum depletion. Eur J Immunol. 1996;26(11):2573–81.CrossRefPubMedGoogle Scholar
  38. Montiel JL, Monsivais-Urenda A, Figueroa-Vega N, Moctezuma JF, Burgos-Vargas R, Gonzalez-Amaro R, Rosenstein Y. Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010;39(1):50–7.CrossRefPubMedGoogle Scholar
  39. Nonomura C, Kikuchi J, Kiyokawa N, Ozaki H, Mitsunaga K, Ando H, et al. CD43, but not P-selectin glycoprotein ligand-1, functions as an E-selectin counter-receptor in human pre-B-cell leukemia NALL-1. Cancer Res. 2008;68(3):790–9.CrossRefPubMedGoogle Scholar
  40. Onami TM, Harrington LE, Williams MA, Galvan M, Larsen CP, Pearson TC, et al. Dynamic regulation of T cell immunity by CD43. J Immunol. 2002;168(12):6022–31.CrossRefPubMedGoogle Scholar
  41. Ostberg JR, Barth RK, Frelinger JG. The Roman god Janus: a paradigm for the function of CD43. Immunol Today. 1998;19(12):546–50.CrossRefPubMedGoogle Scholar
  42. Pallant A, Eskenazi A, Mattei MG, Fournier RE, Carlsson SR, Fukuda M, Frelinger JG. Characterization of cDNAs encoding human leukosialin and localization of the leukosialin gene to chromosome 16. Proc Natl Acad Sci USA. 1989;86(4):1328–32.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Pedraza-Alva G, Rosenstein Y. CD43: one molecule, many tales to recount. Signal Transduction. 2007;7:372–85.CrossRefGoogle Scholar
  44. Remold-O’Donnell E, Kenney DM, Parkman R, Cairns L, Savage B, Rosen FS. Characterization of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Exp Med. 1984;159(6):1705–23.CrossRefPubMedGoogle Scholar
  45. Ruhl S, Cisar JO, Sandberg AL. Identification of polymorphonuclear leukocyte and HL-60 cell receptors for adhesins of Streptococcus gordonii and Actinomyces naeslundii. Infect Immun. 2000;68(11):6346–54.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Sakkas LI, Scanzello C, Johanson N, Burkholder J, Mitra A, Salgame P, et al. T cells and T-cell cytokine transcripts in the synovial membrane in patients with osteoarthritis. Clin Diagn Lab Immunol. 1998;5(4):430–7.PubMedPubMedCentralGoogle Scholar
  47. Seo W, Ziltener HJ. CD43 processing and nuclear translocation of CD43 cytoplasmic tail are required for cell homeostasis. Blood. 2009;114(17):3567–77.CrossRefPubMedGoogle Scholar
  48. Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, Klein JR, Bluestone JA, Thompson CB. CD43 is a murine T cell costimulatory receptor that functions independently of CD28. J Exp Med. 1995;182(1):139–46.CrossRefPubMedGoogle Scholar
  49. Szabady RL, Lokuta MA, Walters KB, Huttenlocher A, Welch RA. Modulation of neutrophil function by a secreted mucinase of Escherichia coli O157:H7. PLoS Pathog. 2009;5(2):e1000320.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Tuccillo FM, de Laurentiis A, Camillo Palmieri C, Fiume G, Bonelli P, Borrelli A, et al. Aberrant glycosylation as biomarker for cancer: Focus on CD43. BioMed Res Int. 2014;2014:742831. doi:10.1155/2014/742831. Epub 2014 Feb 13.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Velázquez F, Grodecki-Pena A, Knapp A, Salvador AM, Nevers T, Croce KJ, et al. CD43 functions as an E-selectin ligand for Th17 cells in vitro and is required for rolling on the vascular endothelium and Th17 cell recruitment during inflammation in vivo. J Immunol. 2016;196(3):1305–16. doi:10.4049/jimmunol.1501171. Epub 2015 Dec 23.CrossRefPubMedGoogle Scholar
  52. Zemelman BV, Chu SH, Walker WA. Host response to Escherichia coli heat-labile enterotoxin via two microvillus membrane receptors in the rat intestine. Infect Immun. 1989;57(10):2947–52.PubMedPubMedCentralGoogle Scholar
  53. Zhou H, Yan H, Cannon JL, Springer LE, Green JM, Pham CTN. CD43-mediated IFN-g production by CD8+ T cells promotes abdominal aortic aneurysm in mice. J Immunol. 2013;190(10):5078–85. doi:10.4049/jimmunol.1203228. Epub 2013 Apr 12.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Alvaro Torres-Huerta
    • 1
  • Estefania Aleman-Navarro
    • 1
  • Maria Elena Bravo-Adame
    • 1
  • Monserrat Alba Sandoval-Hernandez
    • 1
  • Oscar Arturo Migueles-Lozano
    • 1
  • Yvonne Rosenstein
    • 1
  1. 1.Instituto de BiotecnologíaUniversidad Nacional Autónoma de MéxicoCuernavacaMexico